Trial · NCT02152007
Results by group47
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 47
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Evaluation of Systemic Absorption Through Measurement of Serum Sirolimus Trough Levels | Split-body 1% Sirolimus Cream (TD201 1%) | Visit 1, Baseline, <2.0 ng/mL | 15 | participants | |
| Evaluation of Systemic Absorption Through Measurement of Serum Sirolimus Trough Levels | Split-body 1% Sirolimus Cream (TD201 1%) | Visit 2, Week 3, <2 ng/mL | 15 | participants | |
| Evaluation of Systemic Absorption Through Measurement of Serum Sirolimus Trough Levels | Split-body 1% Sirolimus Cream (TD201 1%) | Visit 3, Week 7, <2 ng/mL | 15 | participants | |
| Evaluation of Systemic Absorption Through Measurement of Serum Sirolimus Trough Levels | Split-body 1% Sirolimus Cream (TD201 1%) | Visit 4, Week 13, <2 ng/mL | 14 | participants | |
| Evaluation of Systemic Absorption Through Measurement of Serum Sirolimus Trough Levels | Split-body 1% Sirolimus Cream (TD201 1%) | Visit 5, Week 17, <2 ng/mL | 14 | participants | |
| Evaluation of Systemic Absorption Through Measurement of Serum Sirolimus Trough Levels | Split-body 1% Sirolimus Cream (TD201 1%) | Visit 6, Week 25, <2 ng/mL | 14 | participants | |
| Evaluation of Systemic Absorption Through Measurement of Serum Sirolimus Trough Levels | Split-body 1% Sirolimus Cream (TD201 1%) | Visit 7, Week 37, <2 ng/mL | 14 | participants | |
| Investigator Assessment of Local Tolerability | Split-body 1% Sirolimus Cream (TD201 1%) | Visit 1 Pre, Erythema Score (0-3) | 0.2 | Standard Deviation 0.41 | units on a scale |
| Investigator Assessment of Local Tolerability | Placebo Cream (Vehicle Control) | Visit 1 Pre, Erythema Score (0-3) | 0.2 | Standard Deviation 0.41 | units on a scale |
| Investigator Assessment of Local Tolerability | Split-body 1% Sirolimus Cream (TD201 1%) | Visit 1 Pre, Pruritus Score (0-3) | 0.1 | Standard Deviation 0.26 | units on a scale |
| Investigator Assessment of Local Tolerability | Placebo Cream (Vehicle Control) | Visit 1 Pre, Pruritus Score (0-3) | 0 | Standard Deviation 0 | units on a scale |
| Investigator Assessment of Local Tolerability | Split-body 1% Sirolimus Cream (TD201 1%) | Visit 1 Pre, Stinging/Burning (0-3) Score | 0 | Standard Deviation 0 | units on a scale |
| Investigator Assessment of Local Tolerability | Placebo Cream (Vehicle Control) | Visit 1 Pre, Stinging/Burning (0-3) Score | 0.1 | Standard Deviation 0.26 | units on a scale |
| Investigator Assessment of Local Tolerability | Split-body 1% Sirolimus Cream (TD201 1%) | Visit 1 Pre, Crusting/Erosion Score (0-3) | 0.1 | Standard Deviation 0.26 | units on a scale |
| Investigator Assessment of Local Tolerability | Placebo Cream (Vehicle Control) | Visit 1 Pre, Crusting/Erosion Score (0-3) | 0.1 | Standard Deviation 0.26 | units on a scale |
| Investigator Assessment of Local Tolerability | Split-body 1% Sirolimus Cream (TD201 1%) | Visit 1 Post, Erythema Score (0-3) | 0.2 | Standard Deviation 0.41 | units on a scale |
| Investigator Assessment of Local Tolerability | Placebo Cream (Vehicle Control) | Visit 1 Post, Erythema Score (0-3) | 0.2 | Standard Deviation 0.41 | units on a scale |
| Investigator Assessment of Local Tolerability | Split-body 1% Sirolimus Cream (TD201 1%) | Visit 1 Post, Pruritus Score (0-3) | 0 | Standard Deviation 0 | units on a scale |
| Investigator Assessment of Local Tolerability | Placebo Cream (Vehicle Control) | Visit 1 Post, Pruritus Score (0-3) | 0 | Standard Deviation 0 | units on a scale |
| Investigator Assessment of Local Tolerability | Split-body 1% Sirolimus Cream (TD201 1%) | Visit 1 Post, Stinging/Burning Score (0-3) | 0 | Standard Deviation 0 | units on a scale |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02152007/results